CROI 2014: Neurologic complications of HIV infection

Topics in Antiviral Medicine

Volumn 22, Issue 2, 2014, Pages 594-601

  Spudich, Serena S ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Biomarker; Central nervous system; CROI 2014; Dementia; HAND; HIV; HIV associated neurocognitive disorder; Neuroimaging; Neurology; Neuropathy; Viral escape

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADVERSE DRUG REACTION; AIDS DEMENTIA COMPLEX; COMPLICATION; HIV INFECTIONS; HUMAN;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS;

EID: 84906889413     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Heaton RK, Clifford DB, Franklin DRJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096.
2. Cysique LA, Brew BJ. Prevalence of nonconfounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011;17(2):176-183.
3. Cardenas VA, Meyerhoff DJ, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009;15(4):324-333.
4. Jessen KJ, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9(2):e88591.
5. Edén A, Fuchs D, Hagberg L, et al. HIV- 1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12): 1819-1825.
6. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010; 50(5):773-778.
7. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. JAIDS. 2008;47(2):168-173.
8. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625-633.
9. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73(16): 1292-1299.
10. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75(10):864-873.
11. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76(5): 444-450.
12. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. JAIDS. 2012;60(4):351-358.
13. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration- effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70.
14. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148.